Skip to main content
Erschienen in:

01.02.2011

Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II)

verfasst von: Siobhan Gallanagh, Davide Castagno, Ben Wilson, Erland Erdmann, Faiez Zannad, Willem J. Remme, José L. Lopez-Sendon, Philippe Lechat, Ferenc Follath, Christer Höglund, Viacheslav Mareev, Zygmunt Sadowski, Ricardo J. Seabra-Gomes, Henry J. Dargie, John J. V. McMurray

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims

We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social interactions, satisfaction with sexual relationships, days in bed, days with restricted activity and overall satisfaction with health status. The FSQ was compared to the Minnesota Living with Heart Failure questionnaire (MLwHF).

Methods and results

The FSQ was evaluated in a substudy (n = 340) of the second Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II), a placebo-controlled mortality trial. 265 patients (75%) patients completed both questionnaires at 6 months of follow-up. Both questionnaires indicated substantially impaired QoL. The FSQ demonstrated high internal consistency (Cronbach’s α > 0.7 for all items except “social activity” = 0.66) and construct and concurrent validity. After 6 months, the only item on either questionnaire to show a difference between the placebo- and bisoprolol-treatment groups was the single item FSQ question about “days in bed” (p = 0.018 in favour of bisoprolol).

Conclusions

The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hobbs FDR, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–76.PubMedCrossRef Hobbs FDR, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–76.PubMedCrossRef
2.
Zurück zum Zitat Jeunger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–41.CrossRef Jeunger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–41.CrossRef
3.
Zurück zum Zitat Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalisation in 5025 patients with congestive heart failure. Am J Cardiol. 1996;78:890–5.PubMedCrossRef Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalisation in 5025 patients with congestive heart failure. Am J Cardiol. 1996;78:890–5.PubMedCrossRef
4.
Zurück zum Zitat Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–24.PubMedCrossRef Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–24.PubMedCrossRef
5.
Zurück zum Zitat Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living with Heart Failure Questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail. 1995;1:201–6.PubMedCrossRef Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living with Heart Failure Questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail. 1995;1:201–6.PubMedCrossRef
6.
Zurück zum Zitat Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999;16:247–71.PubMedCrossRef Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999;16:247–71.PubMedCrossRef
7.
Zurück zum Zitat Rector TS, Kubo SH, Cohn JN. Patient’s self assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure: the Minnesota Living with Heart Failure questionnaire. Heart Fail. 1987;3:198–219. Rector TS, Kubo SH, Cohn JN. Patient’s self assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure: the Minnesota Living with Heart Failure questionnaire. Heart Fail. 1987;3:198–219.
8.
Zurück zum Zitat Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med. 1986;1:143–9.PubMedCrossRef Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med. 1986;1:143–9.PubMedCrossRef
9.
Zurück zum Zitat Soderback I, Schult ML, Nordemar R. Assessment of patients with chronic back pain using the Functional Status Questionnaire. Scand J Rehab Med. 1993;25:139–43. Soderback I, Schult ML, Nordemar R. Assessment of patients with chronic back pain using the Functional Status Questionnaire. Scand J Rehab Med. 1993;25:139–43.
10.
Zurück zum Zitat Bostrom C, Harms-ringdahl K, Nordemar R. Relationships between measurements of impairment, disability, pain and disease activity in rheumatoid arthritis patients with shoulder problems. Scand J Rheumatol. 1995;24:352–9.PubMedCrossRef Bostrom C, Harms-ringdahl K, Nordemar R. Relationships between measurements of impairment, disability, pain and disease activity in rheumatoid arthritis patients with shoulder problems. Scand J Rheumatol. 1995;24:352–9.PubMedCrossRef
11.
Zurück zum Zitat Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMed Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMed
12.
Zurück zum Zitat Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRef Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRef
13.
Zurück zum Zitat Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. J Neurol Neurosurg Psychiatry. 1998;65:460–6.PubMedCrossRef Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. J Neurol Neurosurg Psychiatry. 1998;65:460–6.PubMedCrossRef
14.
Zurück zum Zitat Tedesco C, Manning S, Lindsay R, et al. Functional assessment of elderly patients after percutaneous aortic balloon valvuloplasty: New York Heart Association classification versus functional status questionnaire. Heart Lung. 1990;19:118–25.PubMed Tedesco C, Manning S, Lindsay R, et al. Functional assessment of elderly patients after percutaneous aortic balloon valvuloplasty: New York Heart Association classification versus functional status questionnaire. Heart Lung. 1990;19:118–25.PubMed
15.
Zurück zum Zitat Riedinger MS, Dracup KA, Brecht M, et al. Quality of life in patients with heart failure: do gender differences exist? Heart Lung. 2001;30:105–16.PubMedCrossRef Riedinger MS, Dracup KA, Brecht M, et al. Quality of life in patients with heart failure: do gender differences exist? Heart Lung. 2001;30:105–16.PubMedCrossRef
16.
Zurück zum Zitat Investigators CIBIS-II. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRef Investigators CIBIS-II. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRef
17.
Zurück zum Zitat Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundam Clin Pharmacol. 1997; 11:138–42 Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundam Clin Pharmacol. 1997; 11:138–42
18.
Zurück zum Zitat Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91.PubMedCrossRef Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91.PubMedCrossRef
19.
Zurück zum Zitat Cleland JGF, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the Cardiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009;157:457–66.PubMedCrossRef Cleland JGF, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the Cardiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009;157:457–66.PubMedCrossRef
20.
Zurück zum Zitat Majani G, Giardini A, Opasich C, et al. Effect of Valsartan on quality of life when added to Usual Therapy for Heart Failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005;11:253–9.PubMedCrossRef Majani G, Giardini A, Opasich C, et al. Effect of Valsartan on quality of life when added to Usual Therapy for Heart Failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005;11:253–9.PubMedCrossRef
21.
Zurück zum Zitat Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the metoprolol CR/XL randomized intervention trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.PubMedCrossRef Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the metoprolol CR/XL randomized intervention trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.PubMedCrossRef
22.
Zurück zum Zitat Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173–9.PubMedCrossRef Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173–9.PubMedCrossRef
23.
Zurück zum Zitat Yarnold PR, Stille FC, Martin GJ. Cross-sectional psychometric assessment of the functional status questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Int J Psychiatry Med. 1995;25:305–17.PubMedCrossRef Yarnold PR, Stille FC, Martin GJ. Cross-sectional psychometric assessment of the functional status questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Int J Psychiatry Med. 1995;25:305–17.PubMedCrossRef
24.
Zurück zum Zitat Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRef Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRef
25.
Zurück zum Zitat Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMed Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMed
26.
Zurück zum Zitat Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;942:800–6. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;942:800–6.
27.
Zurück zum Zitat Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793–9.PubMed Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793–9.PubMed
28.
Zurück zum Zitat Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–31.PubMedCrossRef Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–31.PubMedCrossRef
Metadaten
Titel
Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II)
verfasst von
Siobhan Gallanagh
Davide Castagno
Ben Wilson
Erland Erdmann
Faiez Zannad
Willem J. Remme
José L. Lopez-Sendon
Philippe Lechat
Ferenc Follath
Christer Höglund
Viacheslav Mareev
Zygmunt Sadowski
Ricardo J. Seabra-Gomes
Henry J. Dargie
John J. V. McMurray
Publikationsdatum
01.02.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6284-x

Weitere Artikel der Ausgabe 1/2011

Cardiovascular Drugs and Therapy 1/2011 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Nach dem Nitrospray fünf Minuten mit der Kardio-CT warten!

19.07.2024 Koronare Herzerkrankung Nachrichten

Nach Verabreichung von sublingualem Nitrospray vor einer CT-Koronarangiografie sollte man unbedingt die in Leitlinien empfohlene Wartezeit einhalten, rät ein kardiologisches Team aus Belgien.

Welche Antikoagulation bei Vorhofflimmern und Leberzirrhose?

19.07.2024 Leberzirrhose Nachrichten

Bei einer Auswertung von US-Versicherungsdaten ging es um die Frage, welche Antikoagulation –  Apixaban, Rivaroxaban oder Warfarin – bei Personen mit Leberzirrhose und Vorhofflimmern unterm Strich die beste Prophylaxe-Option ist.     

Mehrgefäßstenosen einzeitig oder zweizeitig eröffnen?

18.07.2024 Gefäßstenosen Nachrichten

Nach einem Herzinfarkt mit Mehrgefäßerkrankung sind bessere Ergebnisse zu erwarten, wenn alle stenotischen Abschnitte revaskularisiert werden. Sollte das in einer oder in mehreren Sitzungen geschehen? Eine Metaanalyse gibt eine klare Antwort.

Erste zielgerichtete Therapie zur Behandlung der hypertrophen obstruktiven Kardiomyopathie

18.07.2024 Kardiomyopathie Nachrichten

Mit Mavacamten von Bristol Myers Squibb ist erstmals eine zielgerichtete Therapie der hypertrophen obstruktiven Kardiomyopathie (HOCM) verfügbar. Der Myosin-Inhibitor verhindert die bei HOCM übermäßige Bildung von Aktin-Myosin-Querbrücken und verbessert die Symptomatik und die Lebensqualität von Betroffenen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.